WCG IPO Presentation Deck

WCG Strategic Growth Initiatives Are Expected to Sustain Topline Growth Capitalize on Our Large and High-Growth Markets +14% 2021-2023 TAM growth CAGR 35 Source: Tufts CSDD, EvaluatePharma 2 Grow Within Our Existing Client Base: Share Gains & Cross Sell $1.6bn opportunity from expanding existing solutions within top 25 clients Further Leverage the WCG Clinical Trial Ecosystem™, the WCG Knowledge Base™ and Our Proprietary Technology Platform 31TB of Real-Time, Regulatory- Grade Data ONL 30 acquisitions since inception in 2012 wcg Continuously Expand Our Platform Through the Acquisition of New Capabilities

View entire presentation